A citation-based method for searching scientific literature

M Schlumberger, L Bastholt, H Dralle, B Jarzab, F Pacini, J W A Smit. Eur Thyroid J 2012
Times Cited: 85







List of co-cited articles
605 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
865
50

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Samuel A Wells, Sylvia L Asa, Henning Dralle, Rossella Elisei, Douglas B Evans, Robert F Gagel, Nancy Lee, Andreas Machens, Jeffrey F Moley, Furio Pacini,[...]. Thyroid 2015
960
48

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
673
41

Medullary thyroid cancer: management guidelines of the American Thyroid Association.
Richard T Kloos, Charis Eng, Douglas B Evans, Gary L Francis, Robert F Gagel, Hossein Gharib, Jeffrey F Moley, Furio Pacini, Matthew D Ringel, Martin Schlumberger,[...]. Thyroid 2009
815
36


Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Rossella Elisei, Barbara Cosci, Cristina Romei, Valeria Bottici, Giulia Renzini, Eleonora Molinaro, Laura Agate, Agnese Vivaldi, Pinuccia Faviana, Fulvio Basolo,[...]. J Clin Endocrinol Metab 2008
324
18

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
858
18

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Razelle Kurzrock, Steven I Sherman, Douglas W Ball, Arlene A Forastiere, Roger B Cohen, Ranee Mehra, David G Pfister, Ezra E W Cohen, Linda Janisch, Forlisa Nauling,[...]. J Clin Oncol 2011
411
17

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Elaine T Lam, Matthew D Ringel, Richard T Kloos, Thomas W Prior, Michael V Knopp, Jiachao Liang, Steffen Sammet, Nathan C Hall, Paul E Wakely, Vasyl V Vasko,[...]. J Clin Oncol 2010
276
17

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Samuel A Wells, Jessica E Gosnell, Robert F Gagel, Jeffrey Moley, David Pfister, Julie A Sosa, Michael Skinner, Annetta Krebs, James Vasselli, Martin Schlumberger. J Clin Oncol 2010
351
16

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Martin J Schlumberger, Rossella Elisei, Lars Bastholt, Lori J Wirth, Renato G Martins, Laura D Locati, Barbara Jarzab, Furio Pacini, Chantal Daumerie, Jean-Pierre Droz,[...]. J Clin Oncol 2009
257
15

Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
Anne Laure Giraudet, Abir Al Ghulzan, Anne Aupérin, Sophie Leboulleux, Ahmed Chehboun, Frédéric Troalen, Clarisse Dromain, Jean Lumbroso, Eric Baudin, Martin Schlumberger. Eur J Endocrinol 2008
147
15

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
974
15

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
15

Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
Anne Laure Giraudet, Daniel Vanel, Sophie Leboulleux, Anne Aupérin, Clarisse Dromain, Linda Chami, Noël Ny Tovo, Jean Lumbroso, Nathalie Lassau, Guillaume Bonniaud,[...]. J Clin Endocrinol Metab 2007
150
14

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Bruce G Robinson, Luis Paz-Ares, Annetta Krebs, James Vasselli, Robert Haddad. J Clin Endocrinol Metab 2010
181
14


Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardiere, Jan Tennvall, Ahmad Awada, José Manuel Gómez, Françoise Bonichon, Laurence Leenhardt, Christine Soufflet,[...]. Lancet Oncol 2012
244
14

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Nina Karlin, Kostandinos Sideras, John C Morris,[...]. J Clin Endocrinol Metab 2014
73
16

Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.
Giorgio Treglia, Paola Castaldi, Maria Felicia Villani, Germano Perotti, Chiara de Waure, Angelina Filice, Valentina Ambrosini, Nadia Cremonini, Monica Santimaria, Annibale Versari,[...]. Eur J Nucl Med Mol Imaging 2012
93
12

Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level.
Andreas Machens, Ulrich Schneyer, Hans-Jürgen Holzhausen, Henning Dralle. J Clin Endocrinol Metab 2005
173
12

New therapeutic approaches to treat medullary thyroid carcinoma.
Martin Schlumberger, Francesca Carlomagno, Eric Baudin, Jean Michel Bidart, Massimo Santoro. Nat Clin Pract Endocrinol Metab 2008
125
12

Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.
Johannes A A Meijer, Saskia le Cessie, Wilbert B van den Hout, Job Kievit, Johannes W Schoones, Johannes A Romijn, Johannes W A Smit. Clin Endocrinol (Oxf) 2010
95
11

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
L M Mulligan, J B Kwok, C S Healey, M J Elsdon, C Eng, E Gardner, D R Love, S E Mole, J K Moore, L Papi. Nature 1993
11

Chemoembolization for liver metastases from medullary thyroid carcinoma.
J Fromigué, T De Baere, E Baudin, C Dromain, S Leboulleux, M Schlumberger. J Clin Endocrinol Metab 2006
62
16

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fortunato Ciardiello, Giampaolo Tortora, Giancarlo Vecchio, Anderson J Ryan, Gabriella Fontanini, Alfredo Fusco, Massimo Santoro. Cancer Res 2002
481
11

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
C Durante, N Haddy, E Baudin, S Leboulleux, D Hartl, J P Travagli, B Caillou, M Ricard, J D Lumbroso, F De Vathaire,[...]. J Clin Endocrinol Metab 2006
932
11

Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.
E Modigliani, R Cohen, J M Campos, B Conte-Devolx, B Maes, A Boneu, M Schlumberger, J C Bigorgne, P Dumontier, L Leclerc,[...]. Clin Endocrinol (Oxf) 1998
356
11

Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Saila Kauhanen, Camilla Schalin-Jäntti, Marko Seppänen, Sami Kajander, Sami Virtanen, Jukka Schildt, Irina Lisinen, Aapo Ahonen, Ilkka Heiskanen, Mika Väisänen,[...]. J Nucl Med 2011
56
16

Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
Jacques Barbet, Loïc Campion, Françoise Kraeber-Bodéré, Jean-François Chatal. J Clin Endocrinol Metab 2005
225
10

Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.
Claudia Scollo, Eric Baudin, Jean-Paul Travagli, Bernard Caillou, Nicolas Bellon, Sophie Leboulleux, Martin Schlumberger. J Clin Endocrinol Metab 2003
230
10

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
H Donis-Keller, S Dou, D Chi, K M Carlson, K Toshima, T C Lairmore, J R Howe, J F Moley, P Goodfellow, S A Wells. Hum Mol Genet 1993
10

Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
Andreas Machens, Henning Dralle. J Clin Endocrinol Metab 2010
158
10

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Ezra E W Cohen, Lee S Rosen, Everett E Vokes, Merrill S Kies, Arlene A Forastiere, Francis P Worden, Madeleine A Kane, Eric Sherman, Sinil Kim, Paul Bycott,[...]. J Clin Oncol 2008
463
10

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Elizabeth Fox, Brigitte C Widemann, Meredith K Chuk, Leigh Marcus, Alberta Aikin, Patricia O Whitcomb, Maria J Merino, Maya Lodish, Eva Dombi, Seth M Steinberg,[...]. Clin Cancer Res 2013
95
10

Guidelines for the management of thyroid cancer.
Petros Perros, Kristien Boelaert, Steve Colley, Carol Evans, Rhordi M Evans, Georgina Gerrard Ba, Jackie Gilbert, Barney Harrison, Sarah J Johnson, Thomas E Giles,[...]. Clin Endocrinol (Oxf) 2014
645
10

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
192
10

Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.
Rossella Elisei, Valeria Bottici, Fabiana Luchetti, Giancarlo Di Coscio, Cristina Romei, Lucia Grasso, Paolo Miccoli, Pietro Iacconi, Fulvio Basolo, Aldo Pinchera,[...]. J Clin Endocrinol Metab 2004
286
9

Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules.
Giuseppe Costante, Domenico Meringolo, Cosimo Durante, Davide Bianchi, Maria Nocera, Salvatore Tumino, Umberto Crocetti, Marco Attard, Marianna Maranghi, Massimo Torlontano,[...]. J Clin Endocrinol Metab 2007
205
9

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger,[...]. Thyroid 2009
9

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Stephen R Wedge, Donald J Ogilvie, Michael Dukes, Jane Kendrew, Rosemary Chester, Janet A Jackson, Sarah J Boffey, Paula J Valentine, Jon O Curwen, Helen L Musgrove,[...]. Cancer Res 2002
724
9

Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Raffaele Ciampi, Caterina Mian, Laura Fugazzola, Barbara Cosci, Cristina Romei, Susi Barollo, Valentina Cirello, Valeria Bottici, Giulia Marconcini, Pelizzo Maria Rosa,[...]. Thyroid 2013
109
9

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Kostandinos Sideras, John C Morris, Bryan McIver,[...]. Lancet Oncol 2010
308
9

Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Marie-Hélène Massicotte, Maryse Brassard, Médéric Claude-Desroches, Isabelle Borget, Françoise Bonichon, Anne-Laure Giraudet, Christine Do Cao, Cécile N Chougnet, Sophie Leboulleux, Eric Baudin,[...]. Eur J Endocrinol 2014
71
11

Phase II trial of sorafenib in advanced thyroid cancer.
Vandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, Kanchan Puttaswamy, Maryann Redlinger, Kathy Ransone, Susan J Mandel, Keith T Flaherty, Laurie A Loevner, Peter J O'Dwyer,[...]. J Clin Oncol 2008
499
9

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Laurie L Carr, David A Mankoff, Bernardo H Goulart, Keith D Eaton, Peter T Capell, Elizabeth M Kell, Julie E Bauman, Renato G Martins. Clin Cancer Res 2010
286
9

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Laura D Locati, Lisa Licitra, Laura Agate, Sai-Hong I Ou, Andree Boucher, Barbara Jarzab, Shukui Qin, Madeleine A Kane, Lori J Wirth, Connie Chen,[...]. Cancer 2014
74
10

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
137
9

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.